Switch theme
Sign up to access all valuation multiples
PharmaEssentia Corp is engaged in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug pattern developments. It focuses on Hematology, Oncology, and Infectious Disease. The company derives its revenue from sales of medicine products.
2000
321
LTM Revenue $320M
LTM EBITDA $34.8M
$5.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PharmaEssentia has a last 12-month revenue of $320M and a last 12-month EBITDA of $34.8M.
In the most recent fiscal year, PharmaEssentia achieved revenue of $156M and an EBITDA of -$20.5M.
PharmaEssentia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PharmaEssentia valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $87.9M | $156M | $295M | $320M | XXX |
| Gross Profit | $8.5M | $63.1M | $137M | XXX | XXX |
| Gross Margin | 10% | 41% | 46% | XXX | XXX |
| EBITDA | -$48.7M | -$20.5M | $22.9M | $34.8M | XXX |
| EBITDA Margin | -55% | -13% | 8% | 11% | XXX |
| Net Profit | -$85.8M | -$41.9M | -$19.0M | XXX | XXX |
| Net Margin | -98% | -27% | -6% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, PharmaEssentia's stock price is TWD 640 (or $20).
PharmaEssentia has current market cap of TWD 206B (or $6.3B), and EV of TWD 187B (or $5.7B).
See PharmaEssentia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.7B | $6.3B | XXX | XXX | XXX | XXX | $0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, PharmaEssentia has market cap of $6.3B and EV of $5.7B.
PharmaEssentia's trades at 17.8x LTM EV/Revenue multiple, and 163.8x LTM EBITDA.
Analysts estimate PharmaEssentia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PharmaEssentia and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.7B | XXX | XXX | XXX |
| EV/Revenue | 19.3x | XXX | XXX | XXX |
| EV/EBITDA | 249.0x | XXX | XXX | XXX |
| P/E | 83.7x | XXX | XXX | XXX |
| P/E/Growth | 0.9x | XXX | XXX | XXX |
| EV/FCF | 131.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPharmaEssentia's NTM/LTM revenue growth is 54%
PharmaEssentia's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, PharmaEssentia's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PharmaEssentia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PharmaEssentia and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 90% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -212% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 62% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 42% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 40% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 44% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 126% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmaEssentia acquired XXX companies to date.
Last acquisition by PharmaEssentia was XXXXXXXX, XXXXX XXXXX XXXXXX . PharmaEssentia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was PharmaEssentia founded? | PharmaEssentia was founded in 2000. |
| Where is PharmaEssentia headquartered? | PharmaEssentia is headquartered in Taiwan. |
| How many employees does PharmaEssentia have? | As of today, PharmaEssentia has 321 employees. |
| Who is the CEO of PharmaEssentia? | PharmaEssentia's CEO is Mr. Ko-Chung Lin. |
| Is PharmaEssentia publicy listed? | Yes, PharmaEssentia is a public company listed on TAI. |
| What is the stock symbol of PharmaEssentia? | PharmaEssentia trades under 6446 ticker. |
| When did PharmaEssentia go public? | PharmaEssentia went public in 2014. |
| Who are competitors of PharmaEssentia? | Similar companies to PharmaEssentia include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of PharmaEssentia? | PharmaEssentia's current market cap is $6.3B |
| What is the current revenue of PharmaEssentia? | PharmaEssentia's last 12-month revenue is $320M. |
| What is the current EBITDA of PharmaEssentia? | PharmaEssentia's last 12-month EBITDA is $34.8M. |
| What is the current EV/Revenue multiple of PharmaEssentia? | Current revenue multiple of PharmaEssentia is 17.8x. |
| What is the current EV/EBITDA multiple of PharmaEssentia? | Current EBITDA multiple of PharmaEssentia is 163.8x. |
| What is the current revenue growth of PharmaEssentia? | PharmaEssentia revenue growth between 2023 and 2024 was 90%. |
| Is PharmaEssentia profitable? | Yes, PharmaEssentia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
